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The interaction between blood and foreign surfaces of
extracorporeal circuits initiates deposition of the com-
plement component C3b, which in turn amplifies the
alternative complement pathway, resulting in the
release of C3a and C5a and formation of the membrane
Myocardial ischemia and reperfusion stimulate thegeneration of complement by the alternative1,2 and
the classical3 pathways. In addition, the complement
cascade is further augmented during cardiopulmonary
bypass by interaction with extracorporeal surfaces.4-7
Objectives: This study tested the hypothesis that a recombinant human C5a
antagonist, CGS 32359, attenuates neutrophil activation and reduces infarct
size in a porcine model of surgical revascularization.
Methods: CGS 32359 (0.16-16 µmol/L) dose-dependently inhibited super-
oxide production by human C5a-activated porcine neutrophils (18 ± 3.7 vs
1.6 ± 0.5 nmol/5 min/5 × 106 neutrophils; P < .05) and reduced neutrophil
adherence to coronary endothelium from 194 ± 9 to 43 ± 6 neutrophils/mm2
(P < .05). The left anterior descending coronary artery was occluded for 50
minutes, after which saline solution (n = 8), mannitol-buffer vehicle (n = 9,
102 mg/kg bolus, 102 mg · kg–1 · h–1), or CGS 32359 (CGS, n = 7, 60 mg/kg
bolus, 60 mg · kg–1 · h–1) was infused. After ischemia, 1-hour arrest was
achieved by means of multidose hypothermic (4°C) blood cardioplegia, fol-
lowed by 2.5 hours of off-bypass reperfusion. The ligature on the left anteri-
or descending artery was released before the second infusion of cardioplegic
solution.
Results: Area at risk was similar in all groups (saline solution, 27% ± 2%;
mannitol-buffer vehicle, 26% ± 2%; CGS, 26% ± 2% left ventricular mass).
Infarct size (area necrosis/area at risk) was significantly reduced by CGS
(18% ± 6%, P < .05) versus saline solution (52% ± 3%) and mannitol-buffer
vehicle (60% ± 4%). Postischemic systolic shortening (sonomicrometry) in
the area at risk was significantly improved with CGS (0.8% ± 0.9%) com-
pared with saline solution (–3.7% ± 1.1%) and mannitol-buffer vehicle
(–6.4% ± 1.0%). Myeloperoxidase activity from accumulated neutrophils
was less in the ischemic zone of CGS (0.014 ± 0.002 U/100 mg tissue; P <
.05) than mannitol-buffer vehicle (0.133 ± 0.012 U/100 mg tissue).
Conclusions: We conclude that the recombinant human C5a receptor antag-
onist CGS 32359 inhibits surgical ischemia-reperfusion injury after coronary
occlusion. (J Thorac Cardiovasc Surg 2000;120:350-8) 
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Cell Science, Malvern, Pa)19 were incubated with coronary
artery segments in culture dishes alone or in combination
with different concentrations of CGS 32359. Recombinant
human C5a (rhC5a; 100 nmol/L) was used to activate the
adhesion process. Adherence was determined by counting the
number of PMNs adhering to the endothelial surface per
square millimeter in 6 separate microscopic fields under epi-
fluorescent microscopy (490-nm excitation, 504-nm emis-
sion), as described previously.19
In vivo studies 
Surgical procedure. All animals received humane care in
compliance with the “Guide for the Care and Use of
Laboratory Animals” prepared by the Institute of Laboratory
Animal Resources and published by the National Institutes of
Health (National Institutes of Health publication No. 85-23,
revised 1985). The protocol was approved by the Emory
University Institutional Animal Care and Use Committee.
Micropigs weighing 10 ± 3 kg were premedicated with intra-
muscular ketamine (30 mg/kg), xylazine (20 mg/kg), and
diazepam (0.2 mg/kg). The left femoral artery and vein were
catheterized for pressure monitoring and venous access for
intravenous anesthesia (ketamine 8 mg · kg–1 · h–1, xylazine 5
mg · kg–1 · h–1, and diazepam 0.2 mg · kg–1 · h–1 supplemented
with fentanyl citrate [2.0 µg/kg every 30 minutes]) and fluid
administration. The pig was intubated through a tracheotomy
and the lungs were ventilated by a volume-cycled respirator
with oxygen-enriched (50%) room air. Ventilatory adjustments
were made to maintain arterial PO2 greater than 100 mm Hg,
PCO2 between 35 and 45 mm Hg, and pH between 7.35 and
7.45; acidemia was counteracted with sodium bicarbonate.
The chest was opened by means of a median sternotomy.
Umbilical tape snares were placed loosely around the inferi-
or and superior venae cavae, and the hemiazygous vein was
ligated. The pericardium was opened and tented, and Millar
MPC-500 temperature-compensating pressure transducers
(Millar Instruments, Inc, Houston, Tex) were placed in the
aorta through the right internal thoracic artery and in the left
ventricle through an apical puncture. Pairs of sonomicrome-
ter piezoelectric crystals were implanted in the subendocardi-
um of the myocardium perfused by the distal left anterior
descending (LAD) coronary artery (ischemia-reperfusion
area) and within the distribution of the circumflex coronary
artery (nonischemic area).
The animal was prepared for cardiopulmonary bypass
before regional ischemia was imposed. An 8F perfusion can-
nula was placed in the subclavian artery, and the right atrial
appendage was cannulated with single-stage cannulas in the
superior and inferior venae cavae. All cannulas were left in
their most proximal position for later advancement to initiate
cardiopulmonary bypass. A Sarns SMO/INF Infant Mem-
brane Oxygenator (Sarns/3M, Ann Arbor, Mich) was primed
with 300 mL of 6% Hetastarch (Abbott Laboratories, North
Chicago, Ill) and 2 units of donor blood from littermate
Panepinto Micropigs. A 12F catheter was placed through the
left ventricular (LV) apex to vent the left ventricle during car-
diopulmonary bypass.
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attack complex (C5b-9).7 Plasma levels of C3a and, to
a lesser extent, C5a, the plasma accumulation of which
is prevented by avid binding to receptors, have been
shown to be increased in patients undergoing car-
diopulmonary bypass.7,8
Complement plays an important role in initiating and
amplifying neutrophil activation during cardiopul-
monary bypass.9,10 The anaphylatoxin C5a activates both
neutrophils and endothelial cells. Damage to postis-
chemic myocardium and other organs has been correlat-
ed with both the generation of complement and the relat-
ed activation and accumulation of neutrophils.11-13 The
combined stimuli of myocardial ischemia-reperfusion
and cardiopulmonary bypass may therefore exacerbate
postischemic inflammatory responses in patients under-
going cardiopulmonary bypass for the surgical treatment
of ischemic heart disease. Targeting complement com-
ponents, particularly C5a, has been associated with a
reduction in neutrophil activation and accumulation and
a concomitant reduction in postischemic myocardial in-
jury.13-17 However, few experiments have targeted the
C5a anaphylatoxin by intervening at its receptor directly.
The present study tested the hypothesis that C5a
receptor blockade with CGS 32359, a pure antagonist,
inhibits neutrophil function (superoxide generation and
adherence to endothelium) and in vivo manifestations
of postischemic injury (infarct size and regional con-
tractile dysfunction) after simulated surgical revascu-
larization of regionally ischemic myocardium. CGS
32359 is a recombinant derivative of the human C5a
molecule that binds to, but does not activate, the C5a
receptor, thereby acting as an effective antagonist.18
Methods
In vitro studies
Superoxide production by porcine polymorphonuclear
cells. Neutrophils from Yucatan micropigs (Panepinto
Associates, Masonville, Colo) were isolated from peripheral
arterial blood by using the Ficoll-Pacque (Sigma Chemical,
St Louis, Mo) technique, as described previously.19 Final
suspensions contained greater than 95% neutrophils, and
cell viability was greater than 99%, as determined by trypan
blue exclusion. Superoxide anion production by 5 × 106
cells/mL was measured spectrophotometrically (V
max
Kinetic Microliter Plate Reader; Molecular Devices, Palo
Alto, Calif) by using the superoxide dismutase–inhibitive
reduction of ferricytochrome c to ferrocytochrome c, as
described previously.19 Results are reported as nanomoles of
superoxide dismutase–inhibitive superoxide anion produc-
tion per 5 × 106 polymorphonuclear cells (PMNs) per 5 min-
utes of reaction time.
PMN adherence assay. Porcine PMNs (4 × 105 cells/mL)
labeled with Zynaxis PKH26 vital fluorescent dye (Zynaxis
Cardiac myeloperoxidase activity. Tissue samples weigh-
ing approximately 0.4 g from the nonischemic zone and from
the nonnecrotic and necrotic areas of the ischemic zone were
analyzed spectrophotometrically for myeloperoxidase (MPO;
in units per 100 mg of tissue) activity as an assessment of
neutrophil accumulation in the myocardium.21 One unit of
MPO activity is defined as that enzyme activity degrading 1
mmol of H2O2 per minute at 25°C.
Statistical analysis. All time-dependent variables were
analyzed for time and group differences by 2-way analysis
of variance for repeated measures (SigmaStat, SPSS
Science, Chicago, Ill), followed by the Student-Newman-
Keuls multiple range test. Single end-point variables (ie,
AAR size and infarct size) were analyzed by 1-way analy-
sis of variance followed by the Student-Newman-Keuls
multiple range test. Exclusion criteria from further analysis
included (1) failure to complete the protocol; (2) technical
and surgical problems, which compromised the bypass or
cardioplegia or led to failure to follow the protocol; (3) car-
dioversions greater than 4 during ischemia or reperfusion;
or (4) failure to adequately demarcate the AAR with
Unisperse Blue pigment. Means ± SEMs are reported in the
text and figures.
Results
In vitro studies. Superoxide radical generation in
response to increasing concentrations of human C5a is
shown in Fig 1, A. There was a concentration-depen-
dent increase in superoxide radical generation, reach-
ing a maximum at 1 µmol/L without further significant
increase at 10 µmol/L. A concentration of 100 nmol/L
was selected for subsequent in vitro studies.
Fig 1, B, shows the concentration-response curves for
CGS 32359 on neutrophil superoxide radical genera-
tion stimulated by 100 nmol/L human C5a-stimulated
neutrophils. Superoxide radical generation was inhibit-
ed to baseline (control) levels at a concentration of 8
µmol/L CGS 32359, with no further inhibition with 16
µmol/L concentration CGS 32359.
Fig 2, A, shows concentration-dependent stimula-
tion of PMN adherence to porcine coronary artery
endothelium by recombinant human C5a. Human C5a
at 1 µmol/L gave maximal adherence, with no signif-
icant change at a higher concentration. Fig 2, B,
shows inhibition of adherence of C5a-stimulated (100
nmol/L) neutrophils by increasing concentrations of
CGS 32359. Adherence was decreased to unstimulat-
ed levels at a CGS 32359 concentration of 8 µmol/L,
with little further decrease at a concentration of 16
µmol/L.
In vivo studies. Eight experiments were included in
the saline solution group, 9 in the mannitol-buffer vehi-
cle group, and 7 in the CGS 32359 group.
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Protocol. After baseline data were collected, the LAD was
occluded for 50 minutes with the circulation intact (no car-
diopulmonary bypass). The animal was randomized to 1 of 3
groups: saline control, mannitol-buffer vehicle, or CGS
32359. After 40 minutes of occlusion, either saline solution,
mannitol-buffer vehicle, or CGS 32359 was administered as
a bolus followed by continuous infusion; CGS 32359 was
administered at a bolus dose of 60 mg/kg active compound
and 60 mg · kg–1 · h–1 continuous infusion. CGS 32359 was
formulated in a mannitol-buffer lyophilizate containing 37%
active compound by weight.
After 50 minutes of coronary occlusion, the caval cannulas
were advanced, and cardiopulmonary bypass was initiated at
a systemic pressure of 80 mm Hg. The aorta was cross-
clamped, and blood cardioplegic solution (4°C, 10 mEq/L
K+) was delivered for 3 minutes at 50 mm Hg through a
catheter in the proximal aorta simultaneous with systemic
cooling to 28°C ± 1°C. A low K+ (5 mEq/L) blood cardio-
plegic solution was intermittently delivered at 20 and 40 min-
utes of arrest for 2 minutes each (total arrest time, 60 min-
utes). The LAD ligature was removed 5 minutes before the
second delivery of cardioplegic solution to simulate revascu-
larization of the target vessel. A final warm cardioplegic (10
mEq/L K+) formulation was delivered for 3 minutes, after
which the crossclamp was immediately removed. After
electromechanical reanimation was observed, systemic pres-
sure was gradually increased from 50 to 80 mm Hg over 5
minutes. The heart was reperfused for 30 minutes on bypass
(designated as beating empty) and for 2 hours after discon-
tinuation of bypass (designated as beating working).
Data collection. Hemodynamic data, including instanta-
neous LV pressure, arterial pressure, and ischemic zone and
nonischemic zone regional wall motion (systolic shortening
and diastolic characteristics), were collected at baseline, end-
ischemia, and 30, 60, and 120 minutes after terminating car-
diopulmonary bypass on an IBM-compatible computer by
using analog-to-digital conversion (Data Translation
DT2821) and SPECTRUM cardiodynamic data acquisition
and analysis software (Wake Forest University, Winston-
Salem, NC).
Area at risk and infarct size. At the end of each experiment,
the LAD was religated, and 5 mL of Unisperse blue pigment
(Ciba-Geigy, Newport, Del) was injected into the left atrium
to demarcate the in vivo area at risk (AAR). The heart was
arrested with intracardiac sodium pentobarbital, and the heart
was excised. The unstained region of the myocardium (the
AAR) was separated from the blue-stained nonischemic
zone, and the AAR was incubated for 10 minutes in a 37°C
1% solution of buffered (pH 7.4) triphenyltetrazolium chlo-
ride. The area of necrosis relative to the AAR was determined
gravimetrically, as previously described.20
Measurement of plasma CGS 32359. Concentrations of
CGS 32359 in plasma were determined by an enzyme-linked
immunosorbent assay with an antibody that reacted specifi-
cally with CGS 32359 but not with C5a. The working range
of the assay was approximately 0.01 to 1 µg/mL.
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Plasma concentrations of CGS 32359. Systemic plas-
ma concentrations of CGS 32359 generally increased
during the experiment from the initial bolus (22.0 ±
12.7 µg/mL) to the end of the experiment (73.5 ± 8.9
µg/mL); the latter concentration represents approxi-
mately 4 to 4.5 µmol/L. The average concentration of
CGS 32359 in blood cardioplegic solution ranged
between 71% and 82% of that in plasma at correspond-
ing time points, consistent with the dilution associated
with a 4:1 blood/crystalloid ratio.
Hemodynamics. Hemodynamic data are summarized
in Table I. All 3 groups were comparable at baseline in
heart rate; LV peak systolic pressure tended to be
greater in the saline solution and mannitol-buffer vehi-
cle groups than in the CGS 32359 group, but this was
not significant (P = .11). End-diastolic LV pressure was
not significantly different among groups (P = .74).
Mean arterial pressure, however, was significantly
greater in the saline solution group compared with the
CGS group (P = .04), as was positive and negative
dP/dt (P = .03 each).
During LAD occlusion, heart rate increased signifi-
cantly in the mannitol-buffer vehicle group but showed
no significant change in the saline solution or CGS
groups. Heart rate was not statistically different among
groups. LV end-diastolic pressure tended (P = .11) to
increase comparably from baseline values in all groups.
Mean arterial pressure decreased significantly (P = .04)
in the saline solution group but not in the mannitol-
buffer vehicle or CGS groups. However, there were no
significant group differences at this time.
During 30 and 60 minutes of cardiopulmonary
bypass, heart rate was significantly higher in the man-
nitol-buffer vehicle group compared with the saline
solution group, but there were no group differences by
120 minutes of reperfusion. During all 3 time points of
reperfusion, there were no group differences in LV end-
diastolic pressure or mean arterial pressure.
Segmental function. At baseline, segment shortening
in the ischemia-reperfusion zone was comparable
among all 3 groups. During LAD occlusion, ischemic
zone segment shortening decreased significantly (P =
.01) and to comparable values in all 3 groups (Fig 3, A).
Segment shortening at all periods of reperfusion was
significantly less than the respective baseline controls
in all groups, suggesting contractile dysfunction across
all groups. After the first 30 minutes of reperfusion off
bypass, there was still systolic bulging evident in the
saline solution and mannitol-buffer vehicle groups. In
contrast, systolic shortening was positive and signifi-
cantly greater (P = .05) in the CGS 32359 group versus
the mannitol-buffer vehicle group, which persisted for
120 minutes of reperfusion.
There were no group differences in systolic shorten-
ing at baseline. During coronary occlusion, there was
no significant change in systolic shortening in the
groups, although there was a tendency (P = .09) for
shortening to increase in the saline solution group.
However, during 30 minutes of reperfusion off bypass,
there was an increase in shortening in the CGS group,
which was significantly greater (P = .01) than that
found in the saline solution and mannitol-buffer vehicle
Fig 1. A, Superoxide radical generation by porcine PMNs stimulated by increasing concentrations of rhC5a. 
B, Concentration responses of C5a-stimulated superoxide radical generation by porcine PMNs and increasing con-
centrations of CGS 32359. *P < .05 versus control.
A B
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groups (Fig 3, B). Shortening in the saline solution
group decreased by approximately 40%, whereas
shortening in the mannitol-buffer vehicle group
remained comparable with that found during occlusion.
However, any group differences disappeared at 60 and
120 minutes of reperfusion.
Infarct size. There were no statistically significant dif-
ferences among groups in LV weight (P = .06) and
weight of the AAR (saline solution, 10.7 ± 1.0 g; man-
nitol-buffer vehicle, 7.5 ± 0.9 g; CGS 32359, 8.3 ± 1.0 g;
P = .07). The AAR normalized for LV mass showed no
differences among the 3 groups (Fig 4). The area of
necrosis normalized either by the LV mass (Fig 4, mid-
dle panel) or the AAR (Fig 4, bottom panel) was not sig-
nificantly different between the saline solution and man-
nitol-buffer vehicle groups. However, infarct size was
significantly less in the CGS 32359–treated group (P =
.03), whether expressed relative to LV mass or AAR.
MPO activity. Because of technical difficulties, the
MPO values in the saline solution group are not report-
ed. However, values for the mannitol-buffer vehicle
group may serve as a control. As shown in Table II,
there was no significant difference between groups in
MPO activity in the nonischemic myocardium (P =
.99). In the mannitol-buffer vehicle group, MPO activ-
ity in the nonnecrotic and necrotic AARs were signifi-
cantly greater than that in the nonischemic zone. MPO
activity was significantly (P = .01) less in the non-
necrotic and necrotic areas at risk of the CGS 32359
group compared with the same regions in the mannitol-
buffer vehicle group.
Discussion
Complement is involved in the pathophysiology of
myocardial postischemic injury, infarction, and multiple
organ damage referred to as postperfusion syndrome.22
On an organ level, complement products may be activat-
ed locally during myocardial ischemia1-3 but are further
activated during reperfusion.23 Complement products,
such as C3a and C5a, are also activated with exposure of
blood to extracorporeal surfaces, notably oxygenators,
during cardiopulmonary bypass.6,10 Complement C5a
activates neutrophils, consistent with data shown in Figs
1 and 2 of the present study, and the activated neu-
trophils subsequently induce endothelial injury and dam-
age to function and morphology of parenchymal tissue.
Surgical revascularization of acute evolving infarction
with cardiopulmonary bypass and cardioplegia tech-
niques may therefore represent synergistic stimuli from
the pathogenesis of infarction and responses to extracor-
poreal circulation for complement production and con-
sequent complement-mediated injury (direct injury and
neutrophil induced).6 This complement-mediated injury
may aggravate ischemia-reperfusion injury in the surgi-
cal setting and hence may counteract some of the bene-
fits of surgical revascularization. The present study has
shown that the selective C5a receptor antagonist CGS
32359 attenuated neutrophil superoxide generation and
adherence to coronary artery endothelium in vitro and
improved regional postischemic functional recovery and
decreased infarct size in the at-risk myocardium associ-
ated with an attenuation of neutrophil accumulation in
an in vivo model of surgical revascularization. The
Table I.  Hemodynamic variables during the course of the experiment
Group Time HR (beats/min) LVEDP (mm Hg) MAP (mm Hg)
Saline solution Baseline 92.9 ± 8.0 6.3 ± 2.1 114.6 ± 5.0
Ischemia 86.6 ± 4.2 9.1 ± 1.7 80.6 ± 8.0§
BW30 97.9 ± 5.8 16.6 ± 4.1 81.1 ± 5.5
BW60 92.2 ± 2.6 16.2 ± 2.9 89.4 ± 4.3
BW120 94.3 ± 5.4 14.7 ± 2.9 85.7 ± 4.8
Mannitol-buffer vehicle Baseline 76.5 ± 7.9 8.7 ± 0.9 103.6 ± 5.1
Ischemia 103.2 ± 8.6§ 11.3 ± 1.8 90.2 ± 5.1
BW30 118.9 ± 6.5‡ 12.0 ± 2.2 86.9 ± 5.4
BW60 110.9 ± 4.8‡ 15.1 ± 3.6 88.6 ± 5.4
BW120 106.9 ± 5.5 11.0 ± 1.4 83.1 ± 3.5
CGS Baseline 83.6 ± 5.0 8.3 ± 1.1 93.8 ± 5.2*
Ischemia 96.6 ± 7.3 14.4 ± 2.9 78.1 ± 9.4
BW30 116.5 ± 4.6† 15.9 ± 3.7 78.9 ± 4.2
BW60 108.7 ± 7.6 21.9 ± 4.4 91.2 ± 6.3
BW120 105.9 ± 4.6 14.9 ± 2.3 83.5 ± 6.0
HR, heart rate; LVEDP, left ventricular end-diastolic pressure; MAP, mean arterial pressure; BW, Beating working off cardiopulmonary bypass (in minutes).
*P < .05 versus the saline solution group.
†P < .05 versus the mannitol-buffer vehicle group.
‡P < .05 versus the mannitol-buffer vehicle group versus the saline solution group.
§P < .05 versus previous time for each group.
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recovery of regional contractile function with CGS
32359 was modest, although statistically significant, and
may be of little biologic significance or clinical signifi-
cance to the generation of cardiac output. The function-
al recovery (systolic shortening) was independent of
hemodynamic status.
CGS 32359 is a dimeric derivative of C5a with a
truncated C-terminal end. It is a pure C5a receptor
antagonist that binds avidly to human neutrophils and
inhibits the binding of iodine 125–labeled rhC5a to
human neutrophils with a Ki of 2 pmol/L.18 CGS 32359
inhibits C5a-stimulated intracellular calcium mobiliza-
tion with an inhibitory constant (Ki) of 13 ± 4 nmol/L
and attenuates CD11B integrin upregulation (Ki = 1 ±
0.2 nmol/L), superoxide generation (Ki = 282 nmol/L),
and chemotaxis (Ki = 7 ± µmol/L) in human neu-
trophils. Although we used human recombinant C5a to
activate porcine neutrophils in the present study, rather
than using porcine C5a, it is expected that human C5a
has similar responses on porcine neutrophils because
chemical structure and receptor homology are con-
served between the two species. Accordingly, Pellas
and colleagues18 attenuated neutropenia induced by
recombinant human C5a in a porcine (micropigs)
model using CGS 32359, the same species used in the
present study, at a dose of 5 mg/kg. Recombinant
human C5a (5 ng/kg) caused circulating neutrophil
counts in anesthetized micropigs to decrease by 32 ±
3%, which was inhibited by CGS 32359.18 Consistent
with homology between human and porcine recep-
tor–mediated actions of C5a, the present study demon-
strated that CGS 32359 inhibited in vitro rhC5a-stimu-
lated porcine neutrophil superoxide radical production
and adherence to porcine coronary artery endothelium
in a concentration-dependent manner. However, we did
not test CGS 32359 on porcine C5a in vitro in the pre-
sent study.
In contrast to other studies in which complement
therapy was initiated before ischemia (ie, pretreat-
ment),17,24 the C5a antagonist CGS 32359 was effec-
tive at reducing infarct size when administered after
coronary occlusion but before surgical reperfusion. The
underlying mechanism may include a reduction in neu-
trophil-mediated injury and resultant reduction in
infarction. This time window of drug administration is
applicable to surgical revascularization procedures in
which therapeutic agents can be administered before
induction of cardiopulmonary bypass. This study pro-
vides strong evidence that C5a, through receptor-medi-
ated actions, participates in surgically related postper-
fusion and ischemia-reperfusion injury and that C5a
receptor antagonism initiated before surgical reperfu-
sion is an effective therapeutic approach.
Complement fractions act directly on both neutrophils
and vascular endothelium to trigger neutrophil activation
and adherence to endothelium.25,26 C5a, unlike C3a, is a
strong chemotactic factor16,18 and promotes adherence
to the vascular endothelium. In addition, C5a stimulates
the upregulation of the cell surface glycoprotein com-
plexes CD11a/CD18 and CD11b/CD18 on neutro-
phils.27 This upregulation is a rapid response to C5a
involving translocation of preformed integrin complexes
Fig 2. A, Stimulation of porcine PMN adherence to porcine coronary artery endothelium by increasing concentra-
tions of rhC5a. B, Inhibition by CGS 32359 on adherence of C5a-stimulated porcine PMNs to unstimulated coro-
nary artery endothelium. C5a, PMN stimulated with 100 nmol/L rhC5a, no treatment. *P < .05 versus control.
A B
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to the neutrophil plasma membrane. C5a is also a potent
agonist of P-selectin surface expression on endothelial
cells. Therefore, C5a promotes activation of both cell
types involved in inflammatory-related neutrophil-
endothelial cell interactions. Our in vitro studies are con-
sistent with this involvement of C5a by demonstrating
that treatment of neutrophils with rhC5a increases
superoxide radical generation (Fig 1, A) and adherence
to coronary vascular endothelium (Fig 2, A), which was
inhibited by the highly selective C5a receptor antagonist
CGS 32359 (Figs 1, B, and 2, B). The significant reduc-
tion in neutrophil accumulation observed in the in vivo
AAR of the CGS 32359–treated group may have been
the result of a direct inhibition of C5a-mediated neu-
trophil activation or attenuation of adherence to coro-
nary artery and venous endothelium and subsequent
accumulation in this area. Although studies have shown
that both ischemia-reperfusion and cardiopulmonary
bypass increase C5a generation, we did not measure
local or circulating C5a or C5a-desArg in the present
experiment.
Inhibition of complement-mediated mechanisms
have been shown to be beneficial in reducing infarct
size and contractile dysfunction in a number of stud-
ies.23,26,28 Accordingly, inhibition of formation of com-
plement components by complement receptor type
115,29 or with glycosaminoglycans (heparin and sulfat-
ed derivatives)30 or binding of complement compo-
nents into nonactive complexes (complement-antibody
complexes)17 have been therapeutically beneficial.
Pretreatment with a recombinant human soluble com-
plement receptor type 129 reduced complement-activat-
ed neutrophil superoxide generation and postischemic
contractile dysfunction. In a study by Amsterdam and
colleagues,17 pretreatment with a monoclonal antibody
to C5a reduced infarct size by 38% but did not alter
neutrophil accumulation in the AAR. However, the
monoclonal antibody to C5a inhibited C5a-induced
neutrophil aggregation, chemotaxis, and superoxide
generation in vitro in agreement with our observations.
In a porcine model of global ischemia and cardioplegia
protection, Tofukuji and colleagues31 reported that a
Fig 3. Segmental shortening in the ischemia-reperfusion AAR (A) and in the nonischemic zone (B) during the
course of the experiment. SAL, Saline solution group; MANN/BUFF, mannitol-buffer vehicle group; CGS, CGS
32359 group; CNTL, control or baseline; ISCH, coronary occlusion; BW30, BW60, and BW120, minutes after dis-
continuation of cardiopulmonary bypass. *P < .05 versus the saline solution and mannitol-buffer vehicle groups.
Table II. Myocardial MPO activity as an index of neutrophil accumulation within the nonischemic myocardium
and the AAR
Group Nonischemic Nonnecrotic AAR Necrotic AAR
Mannitol-buffer 0.026 ± 0.00865 0.113 ± 0.0773 0.101 ± 0.0227
CGS 32359 0.026 ± 0.00501 0.014 ± 0.0021* 0.0310 ± 0.0119*
All values are given as units per 100 mg of tissue.
*P < .05 versus the mannitol-buffer vehicle group.
A B
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monoclonal antibody to C5a reduced neutrophil accu-
mulation in myocardial tissue postischemically, which
is consistent with observations in the present study
using the receptor antagonist CGS 32359. In addition,
Tofukuji and colleagues also showed that postischemic
coronary arteriolar endothelial function was improved
with a monoclonal antibody to C5a. In a clinical study,
Fitch and colleagues14 demonstrated that a humanized
antibody to C5a reduced leukocyte activation, sC5b-9
production and CK-MB release, and attenuated neu-
rocognitive defect in patients undergoing cardiopul-
monary bypass. Hence, these studies and the present
study support the concept that attenuating C5 and C5a
is an effective therapeutic approach to reducing postis-
chemic injury in the surgical setting where cardiopul-
monary bypass is used.
In summary, the human recombinant C5a antagonist
CGS 32359 inhibited neutrophil superoxide radical pro-
duction and adherence to coronary artery endothelium
stimulated by C5a in porcine in vitro assays. When given
as an intravenous adjunct before surgical revasculariza-
tion, CGS 32359 significantly reduced infarct size and
modestly improved regional systolic functional recovery
independent of hemodynamic changes. A reduction in
MPO activity in the AAR in CGS 32359–treated hearts in
conjunction with the in vitro data suggests a neutrophil-
mediated mechanism of cardioprotection. The present
study strongly suggests that C5a receptor antagonists
administered at a clinically relevant time (before surgical
reperfusion and as an adjunct to cardioplegia) may be an
important therapeutic strategy in reducing the cardiac
consequences of postischemic injury in situations where
direct and neutrophil-mediated effects of complement
contribute to postischemic tissue damage.
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Fig 4. Infarct size data as a percentage of either LV mass (in grams) or AAR. A, AAR normalized for mass of the
LV; B, area of necrosis (An) normalized for LV mass; C, area of necrosis normalized for AAR. Open bar, Saline
solution group; gray bar, mannitol-buffer group; black bar, CGS 32359 group. *P < .05 versus the saline solution
and mannitol-buffer vehicle groups.
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